Lili Chan1, Benjamin Asriel1, Ellen F Eaton2, Christina M Wyatt1. 1. Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Division of Infectious Diseases, Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama, USA.
Abstract
PURPOSE OF REVIEW: The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations. Although TDF is well tolerated, the potential for kidney and bone toxicity has important implications for public health given the large number of individuals exposed to TDF worldwide. This review summarizes the recent literature on kidney and bone health in individuals treated with TDF and the newer prodrug tenofovir alafenamide (TAF). RECENT FINDINGS: Risk factors for TDF toxicity appear to be similar in patients treated for HIV or hepatitis B virus and in HIV-uninfected PrEP users, although drug-drug interactions are a more important concern in HIV-positive individuals. The risk of toxicity appears to be lower with TAF, but further studies are needed to confirm the safety of long-term use and to evaluate the efficacy of TAF-based PrEP. SUMMARY: Nephrologists should be aware of the potential kidney and bone toxicity of TDF, as well as unique situations in which the newer prodrug TAF may contribute to kidney injury.
PURPOSE OF REVIEW: The antiviral agent tenofovir is highly effective for the treatment of HIV and hepatitis B virus infections, and the older prodrug tenofovir disoproxil fumarate (TDF) is also a component of daily preexposure prophylaxis (PrEP) to reduce the risk of HIV infection in high-risk populations. Although TDF is well tolerated, the potential for kidney and bone toxicity has important implications for public health given the large number of individuals exposed to TDF worldwide. This review summarizes the recent literature on kidney and bone health in individuals treated with TDF and the newer prodrug tenofovir alafenamide (TAF). RECENT FINDINGS: Risk factors for TDF toxicity appear to be similar in patients treated for HIV or hepatitis B virus and in HIV-uninfected PrEP users, although drug-drug interactions are a more important concern in HIV-positive individuals. The risk of toxicity appears to be lower with TAF, but further studies are needed to confirm the safety of long-term use and to evaluate the efficacy of TAF-based PrEP. SUMMARY: Nephrologists should be aware of the potential kidney and bone toxicity of TDF, as well as unique situations in which the newer prodrug TAF may contribute to kidney injury.
Authors: José L Casado; Sara Bañón; Carmen Santiuste; Jorge Serna; Paula Guzman; Maite Tenorio; Fernando Liaño; José M del Rey Journal: AIDS Date: 2016-01 Impact factor: 4.177
Authors: Anthony E Zimmermann; Thomas Pizzoferrato; John Bedford; Anne Morris; Robert Hoffman; Gregory Braden Journal: Clin Infect Dis Date: 2005-12-08 Impact factor: 9.079
Authors: Kenneth Mugwanya; Jared Baeten; Connie Celum; Deborah Donnell; Thomas Nickolas; Nelly Mugo; Andrea Branch; Jordan Tappero; James Kiarie; Allan Ronald; Michael Yin; Christina Wyatt Journal: J Infect Dis Date: 2016-03-29 Impact factor: 5.226
Authors: Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Samir K Gupta; Albert M Anderson; Ramin Ebrahimi; Todd Fralich; Hiba Graham; Valeska Scharen-Guivel; John F Flaherty; Claude Fortin; Robert C Kalayjian; Anita Rachlis; Christina M Wyatt Journal: PLoS One Date: 2014-03-20 Impact factor: 3.240
Authors: Eve-Irene Lepist; Xuexiang Zhang; Jia Hao; Jane Huang; Alan Kosaka; Gabriel Birkus; Bernard P Murray; Roy Bannister; Tomas Cihlar; Yong Huang; Adrian S Ray Journal: Kidney Int Date: 2014-03-19 Impact factor: 10.612
Authors: Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister Journal: Lancet Infect Dis Date: 2015-11-02 Impact factor: 25.071
Authors: Lucio Boglione; Ilaria De Benedetto; Valentina Dodaro; Marta Chiecchio; Amedeo De Nicolò; Giovanni Di Perri; Antonio D'Avolio Journal: Arch Virol Date: 2022-05-22 Impact factor: 2.574
Authors: X Q Le; D P Liu; J Chen; Z Y Gong; J N Xun; J R Wang; J J Sun; C Steinhart; L Liu; Y Z Shen; T K Qi; Z Y Wang; X Zhang; Y Tang; W Song; H Z Lu; R F Zhang Journal: HIV Med Date: 2021-06-10 Impact factor: 3.180